CVS Health (NYSE:CVS) Given New $97.00 Price Target at The Goldman Sachs Group

CVS Health (NYSE:CVS) had its price target lifted by The Goldman Sachs Group from $95.00 to $97.00 in a research report report published on Thursday,MarketScreener reports. The firm currently has a buy rating on the pharmacy operator’s stock.

Other equities analysts have also issued reports about the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of CVS Health in a research report on Wednesday, December 10th. Morgan Stanley boosted their price target on shares of CVS Health from $89.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of CVS Health in a research note on Monday, December 29th. UBS Group restated an “outperform” rating on shares of CVS Health in a report on Wednesday, December 10th. Finally, Wells Fargo & Company cut their price target on CVS Health from $103.00 to $102.00 and set an “overweight” rating for the company in a research note on Thursday, November 13th. Nineteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, CVS Health currently has an average rating of “Moderate Buy” and a consensus price target of $94.91.

CVS Health Trading Up 0.9%

NYSE:CVS traded up $0.69 during trading hours on Thursday, hitting $78.62. The stock had a trading volume of 629,912 shares, compared to its average volume of 9,798,964. The business’s 50 day moving average is $78.58 and its 200-day moving average is $75.99. The company has a market cap of $100.02 billion, a price-to-earnings ratio of 56.97, a P/E/G ratio of 0.71 and a beta of 0.50. CVS Health has a one year low of $58.35 and a one year high of $85.15. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.63 and a current ratio of 0.84.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.09. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The firm had revenue of $105.69 billion for the quarter, compared to analyst estimates of $103.67 billion. During the same quarter in the prior year, the company earned $1.19 earnings per share. The business’s revenue for the quarter was up 8.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Sell-side analysts anticipate that CVS Health will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Thursday, January 22nd were issued a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 3.4%. The ex-dividend date of this dividend was Thursday, January 22nd. CVS Health’s dividend payout ratio is currently 700.00%.

Hedge Funds Weigh In On CVS Health

Hedge funds have recently bought and sold shares of the business. Norges Bank purchased a new position in CVS Health during the fourth quarter valued at approximately $1,666,265,000. Wellington Management Group LLP increased its holdings in shares of CVS Health by 391.6% in the 3rd quarter. Wellington Management Group LLP now owns 6,330,717 shares of the pharmacy operator’s stock valued at $477,273,000 after acquiring an additional 5,042,816 shares during the period. Amundi lifted its stake in shares of CVS Health by 95.3% during the 3rd quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock worth $572,665,000 after purchasing an additional 3,637,943 shares during the last quarter. Invesco Ltd. boosted its position in CVS Health by 15.3% during the second quarter. Invesco Ltd. now owns 23,532,479 shares of the pharmacy operator’s stock valued at $1,623,270,000 after purchasing an additional 3,118,626 shares in the last quarter. Finally, Capital Research Global Investors grew its stake in CVS Health by 24.5% in the third quarter. Capital Research Global Investors now owns 11,469,250 shares of the pharmacy operator’s stock valued at $864,667,000 after purchasing an additional 2,253,531 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.